Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.60 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | F2RL3 | Q96RI0 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | F2R | P25116 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2122743 | 0.83 | CYP19A1 (0.66) | CYP19A1ALDH1A1F2RL3MAPTMEN1 | |
| SCHEMBL2421702 | 0.82 | CYP19A1 (0.69) | CYP19A1ALDH1A1F2RL3MAPTMEN1 | |
| SCHEMBL2900943 | 0.82 | CYP19A1 (0.65) | CYP19A1ALDH1A1F2RL3MAPTMEN1 | |
| SCHEMBL2123334 | 0.82 | ALDH1A1 (0.67) | CYP19A1ALDH1A1F2RL3MAPTMEN1 | |
| SCHEMBL30943220 | 0.81 | CYP19A1 (0.67) | CYP19A1ALDH1A1F2RL3MAPTMEN1 | |
| SCHEMBL2124888 | 0.81 | CYP19A1 (0.63) | CYP19A1ALDH1A1F2RL3MAPTMEN1 | |
| SCHEMBL2123821 | 0.81 | CYP19A1 (0.67) | CYP19A1ALDH1A1F2RL3MAPTMEN1 | |
| SCHEMBL16087011 | 0.80 | CYP19A1 (0.66) | CYP19A1ALDH1A1F2RL3MAPTMEN1 | |
| SCHEMBL2125394 | 0.80 | CYP19A1 (0.65) | CYP19A1ALDH1A1F2RL3MAPTMEN1 | |
| SCHEMBL2124014 | 0.80 | CYP19A1 (0.59) | CYP19A1ALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871948-B2 | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2014-10-28 | — | — | US | disclosed |
| EP-2444392-B1 | Intermediary (aza)indole derivative substituted in position 5 | ACRAF (IT) | 2014-09-24 | — | — | EP | disclosed |
| US-20130158269-A1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | AZIENDE CHIMICHE RIUNITE ANGELIN FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2013-06-20 | — | — | US | disclosed |
| EP-2234968-B1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | ACRAF (IT) | 2013-03-27 | — | — | EP | disclosed |
| US-8399477-B2 | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESO A.C.R.A.F. S.P.A. (IT) | 2013-03-19 | — | — | US | disclosed |
| EP-2444392-A1 | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) | 2012-04-25 | — | — | EP | disclosed |
| US-20100286189-A1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | Aziende Chim. Riun.Ang.Franc. A.C.R.A.F.S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
| EP-2234968-A1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) | 2010-10-06 | — | — | EP | disclosed |
| EP-2078711-A1 | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2009-07-15 | — | — | EP | disclosed |
| WO-2009083436-A1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286189-A1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | IDO1, CYP51A1, WEE1 | CYP19A1 28/4885RAD52 3937/4885ALDH1A1 582/4885 |
| US-20130158269-A1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | IDO1, CYP51A1, WEE1 | CYP19A1 28/4885RAD52 3937/4885ALDH1A1 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.